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Abstract 
Background: Non-infectious uveitis is a sight-threatening inflammatory disease that often 
necessitates prolonged use of high-dose corticosteroids, resulting in significant systemic side 
effects. There is a need for efficacious steroid-sparing immunomodulatory therapy for these 
patients, and the mTOR inhibitors (sirolimus and everolimus) may be contenders for this 
role. 
 
Methods: A comprehensive review of preclinical and clinical research on mTOR inhibitors for 
non-infectious uveitis was performed. Articles were identified by a search of MEDLINE 
(PubMed/OVID) and EMBASE (OVID) the terms (uveitis OR non-infectious uveitis) AND 
(mTOR inhibitor OR sirolimus OR everolimus). Assessment of study aims, methods, efficacy 
outcomes and adverse events was performed. 
 
Results: Seven pre-clinical and nine clinical studies were identified. One study in each group 
was on everolimus, the rest sirolimus. Preclinical studies have been performed in rabbit, rat, 
mouse and in-vitro models. Clinical studies range from comparative open-label trials to case 
reports, with reported clinical efficacy ranging from 40% to 100% depending on endpoint 
assessed. The overall rate of drug-related adverse events (such as ocular irritation, visual 
floaters, nausea and vomiting) was 0.640 events per patient-year with sirolimus, and 0.111 
events per patient-year with everolimus. 
 
Conclusion: Published evidence suggests that sirolimus and everolimus may be useful in the 
management of non-infectious uveitis. Both appear to be well tolerated, especially when 
locally administered. Further high-quality RCTs adopting standardised end-points are 
required to definitively determine the efficacy of each agent.  
 
Introduction 
Uveitis (intraocular inflammation) is a serious, potentially blinding condition [1,2,3]. Uveitis 
is described by the anatomical pattern of involvement in the eye (anterior, intermediate, 
posterior or panuveitis), the clinical course of the inflammation (acute, recurrent or 
chronic), and by its aetiology (individual causes within the categories of infectious, non-
infectious, masquerade) [4,5]. In many parts of the world (including the USA and Europe), 
non-infectious uveitis is a significant cause of blindness in the working age group. Most non-
infectious uveitis appears to be autoimmune (or autoinflammatory) in nature [2], either 
occurring as isolated ocular inflammation (usually labelled ‘idiopathic uveitis’) or may be 
associated with systemic conditions in which immune dysregulation is evident (e.g. sarcoid 
uveitis, multiple-sclerosis associated uveitis, etc.) [4,5].  
 
Currently, non-infectious uveitis is treated first-line with corticosteroids [6]. For disease 
restricted to the front of the eye (anterior uveitis) topical therapy may be sufficient, but for 
the more sight-threatening forms which affect more posterior structures (intermediate, 
posterior and panuveitis), local (injections or implants) or systemic therapy (usually as oral 
prednisolone) may be given. Corticosteroids are capable of quickly regaining control of the 
inflammatory state, but high doses are rarely used long-term due to the increased burden of 
side effects that occur [7]. Safe maintenance doses are generally considered to be less than 
10mg of prednisolone per day [8]. 
 
As a result, patients who are not adequately controlled at safe maintenance levels of 
steroids, or cases of uveitis refractory to corticosteroid therapy, require an escalation of 
their treatment to include more powerful second-line therapeutics [8]. These may include 
one or more of the drugs sometimes referred to as ‘DMARD’ (Disease Modifying Anti-
Rheumatic Drug) agents, such as mycophenolate mofetil, azathioprine, methotrexate, 
ciclosporin and tacrolimus [7,8]. Current options include switching to or combining second-
line agents, switching to or combining with a biological therapy (such as adalimumab), or 
using cytotoxic alkylating agents [5,8]. However, a significant proportion of cases at this 
stage still suffer from either poor inflammatory control or excessive side effects. As a result 
there is a growing need for alternative treatment regimens, whether systemic or local, 
which optimise inflammatory control without an overburden of side effects [5]. The 
challenges and morbidity of current treatment regimens are discussed in more detail in a 
number of reviews, highlighting the high patient cost of drug-related morbidity, particularly 
of excessive corticosteroid usage, and the urgent need for better therapies [5,9,10].  
 
One area of recent interest are mTOR inhibitors, a group of immunosuppressant drugs with 
particular effects on the T-cell arm of the adaptive immune system [5,8]. The immune 
dysfunction in most non-infectious uveitis appears to be primarily T-cell mediated [2,11]. T-
cell inhibition by calcineurin inhibitors such as ciclosporin or tacrolimus is already a well-
established part of uveitis treatment strategy. The calcineurin inhibitors act to reduce IL-2 
transcription and prevent the cascade of T-cell activation [12,13]. 
mTOR (mammalian Target Of Rapamycin) is a serine/threonine kinase that acts downstream 
of various cytokine receptors, including the IL-2 receptor, and influences many active cell 
processes [14]. mTOR action in cells is complex, integrating a range of cell signals to direct 
cell metabolism, which in the case of T-cells has been associated with cell differentiation 
[15]. T-cell activation has been associated with mTOR activity, while suppressed T-cell mTOR 
activity in has been associated with quiescence, memory T-cell formation, and increased T-
regulatory cells [15]. 
As a result, the mTOR system may be a desirable therapeutic target for the control of 
autoimmune conditions [15]. mTOR inhibitors, such as sirolimus (Rapamune; Pfizer Inc.) and 
everolimus (Zortress [USA]/Certican [EU and others]; Novartis International AG), bind to the 
FKBP12 protein, and the resulting complex acts to reduce the transcription of mTOR. This 
has a particular effect in T-cells on the mTORC1 complex, associated with signal 
transduction for T-cell activation [15]. This allows mTOR inhibitors to interfere with T-cell 
signal transduction, preventing cytokines such as IL-2 from having a proliferative and 
differentiating effect on T-cells [11,16]. 
Due to the pleiotropic actions of mTOR, mTOR inhibitors can have more wide-ranging 
pharmacological effects than calcineurin inhibitors. mTOR inhibitors have been shown to 
have antiviral properties, where studies have shown inhibitory effects in HIV infections 
[17,18,19]; anti-tumour properties, with studies detailing activity in prostate [20] and breast 
cancers [21,22]; and actions which reduce cell senescence [23]. 
Sirolimus and everolimus have been licensed for human applications for many years, with 
their main indications being transplant immunosuppression and for the treatment of mTOR-
dependent tumours [14]. mTOR inhibition has also been shown to be of potential 
therapeutic use in diseases of autoimmune aetiology, with promise in pre-clinical studies for 
systemic lupus erythematosus [24], experimental allergic encephalomyelitis (as a model for 
multiple sclerosis) [25], rheumatoid arthritis [26] and type 1/insulin dependent diabetes 
mellitus [27]. 
Additionally, a recent trial studied sirolimus in the context of refractory autoimmune 
cytopenia, finding that the agent showed significant improvement for patients with 
autoimmune lymphoproliferative syndrome [28]. The authors especially noted a decrease in 
the number of active T-cells, attributed to the relatively high degree of action that mTOR 
inhibitors have on T-cell activities [28]. The study concluded that sirolimus is a contender for 
steroid-sparing treatment in this autoimmune haematological context [28]. 
Other applications for which the role of mTOR inhibitors has been considered include the 
modulation of restenosis of coronary stents [29], and the prevention of post-traumatic 
epilepsy [30].  
 
While calcineurin inhibitors are well-established in the treatment of uveitis, mTOR inhibitors 
have been little considered within ophthalmology until recently; use of mTOR inhibition 
outside of clinical trials has been largely viewed as a ‘last line’ option for refractory uveitis, 
when almost all other agents have failed or are contraindicated. This appears to be 
changing, as highlighted by the recent undertaking of an international multicentre 
randomised controlled trial in this area. 
It is timely therefore to undertake a comprehensive review examining the evidence for the 
use of mTOR inhibitors in non-infectious uveitis. The review goes beyond the relatively 
narrow scope of the existing narrative summaries in this area [11,31] to include all 
preclinical and clinical research on mTOR inhibitors. This comprehensive approach also 
includes analysis of adverse events.  
 
Materials and Methods 
Searches were conducted of MEDLINE (1946 to April Week 4 2016; via PubMED and Ovid) 
and EMBASE (1974 to 2016 May 10; via Ovid), using the terms (uveitis OR non-infectious 
uveitis) AND (mTOR inhibitor OR sirolimus OR everolimus). The searches had no limitations 
on publication date or language of publication. 
From the search yield, any article which satisfied the following criteria was selected for this 
narrative review: the study intervention was an mTOR inhibitor, either sirolimus or 
everolimus; the disease context was non-infectious uveitis (of any anatomical category). 
Pre-clinical (animal and in vitro studies) and clinical studies (comparative and non-
comparative) were included; there were no age restrictions.  
Review of the studies included detailing the type of research identified and findings with 
regard to the use mTOR inhibitors for non-infectious uveitis. 
Adverse events, adverse reactions and study discontinuations were also assessed for and 
categorised. As per UK NHS National Institute for Health Research nomenclature, an 
“Adverse Event” (AE) is one that is not necessarily deemed related to the study drug, an 
“Adverse Reaction” (AR) is one that is deemed related to the study drug; and a “Serious 
Adverse Event” (SAE) or “Serious Adverse Reaction” (SAR) is an AE or AR resulting in death 
or hospitalisation [32]. 
Results 
Overview 
Sixteen studies were identified, comprising nine clinical studies and seven preclinical studies 
(Table 1). Of the clinical studies, eight investigated sirolimus with a total of 46.87 patient-
years of analysis; one study investigated everolimus with 18 patient-years of analysis. 
Therefore the clinical studies included for review offer a combined total of 64.87 patient-
years of analysis of mTOR inhibitors in non-infectious uveitis. Of the preclinical studies, six 
studies investigated sirolimus and one study investigated everolimus. The reported uveitis 
diagnoses of patients featured in the nine clinical studies are documented in Table 2. 
 
Table 1. Details of included studies 
Study Drug Dose Model/Study Design 
Pre-clinical studies 
Ideka et al. [33] Sirolimus 0.03 to 0.2mg/kg/day Animal study (rat; Experimental 
Autoimmune Uveitis [EAU]) 
Martin et al. [34] 0.01 mg/kg/day Animal study (rat; EAU) 
Roberge et al. [35] 1mg/kg/day Animal study (rat; EAU) 
Zhang et al. [36] 1.5µg to 7.5µg Animal study (mouse; EAU) 
Ohia et al. [37] 10mg/kg Animal study (rabbit; Endotoxin-
Induced Uveitis [EIU]) 
Yang et al. [38] 1-1000ng/ml Human in-vitro study 
(peripheral blood mononuclear 
cells) 
Hennig et al. [39] Everolimus 5mg/kg Animal study (mouse; EAU) 
Clinical studies 
Vigil et al. [40] Sirolimus 352µg intravitreal or 
1320µg subconjunctival, 
as single doses on days 
0, 60, 120; then as 
required from 6 to 12 
months (maximum 3 
Prospective, randomised, 
comparative open label trial 
Ibrahim et al. [41] Prospective, randomised, 
comparative open label trial 
additional doses) 
Nguyen et al. [42] 352µg intravitreal or 
1320µg subconjunctival, 
as single doses on days 
0, 60 and 120 
Prospective, randomised, 
comparative open label trial 
Sen et al. [43] 1320µg subconjunctival, 
single dose 
Prospective non-comparative 
open label trial 
Shanmuganathan et al. 
[44] 
Oral 2 to 12mg per day Prospective non-comparative 
open label trial 
Phillips et al. [45] Oral 1 to 4mg per day, 
to 4-12ng/ml blood 
trough levels 
Case series 
Nussenblatt et al. [46] Oral 3 to 6mg per day Case report 
Nowosielska et al. [47] Unknown Case report 
Heiligenhaus et al. [48] Everolimus Oral 1.5 to 2.5mg per 
day, to 3-8ng/ml serum 
trough levels 
Prospective non-comparative 
open label trial 
 
 
Table 2. Summary of clinical study patient diagnoses 
Diagnosis Patients receiving 
Sirolimus 
Patients receiving 
Everolimus 
Total 
Behçet’s Disease 3 0 3 
Birdshot Chorioretinopathy 4 0 4 
HLA-B27 related 1 0 1 
Idiopathic Uveitis 28 12 40 
Multifocal Choroiditis 2 0 2 
Punctate Inner Choroiditis 3 0 3 
Psoriasis related 1 0 1 
Sarcoidosis 8 0 8 
Secondary to Lyme Disease 1 0 1 
Sympathetic Ophthalmia 1 0 1 
Vogt-Koyanagi-Harada Disease 1 0 1 
Total 53 12 65 
 
 
Sirolimus – preclinical studies 
Six preclinical studies were identified that evaluated sirolimus for use in uveitis. Three 
studies utilised a rat model [33,34,35]; one a mouse model [36]; one a rabbit model [37]; 
and one was an in-vitro study of collected human cells [38]. In all five animal studies 
sirolimus was delivered systemically by intravenous, intraperitoneal or intramuscular 
injection. 
Four animal studies (Ideka et al. [33]; Martin et al. [34]; Roberge et al. [35]; Ohia et al. [37]) 
set sirolimus doses relative to weight, and delivered doses ranged from 0.01mg/kg/day to 
10mg/kg in various trial arms. The fifth study by Zhang et al. [36] used absolute doses of 
sirolimus, administering 1.5µg and 7.5µg doses to mice. 
Three animal studies (Ideka et al. [33]; Roberge et al. [35]; Ohia et al. [37]) used a control 
group of uveitis (EAU or EIU as per study design) with an equivalent sham injection in place 
of sirolimus delivery. Martin et al. [34] used a three-arm design where sirolimus injection 
with a sham ciclosporin injection was compared to ciclosporin with a sham sirolimus 
injection, and sirolimus and ciclosporin co-therapy, all groups on an EAU rat model. Zhang et 
al. [36] used a control group of EAU with no injection. Primary outcomes varied but were 
almost always included a histological evaluation of uveitis and analysis of T-cell number and 
function, accompanied by secondary outcomes of inflammatory cytokine levels, 
immunoglobulin assessments, and toxicity. 
 
All animal studies showed that sirolimus significantly suppressed experimental uveitis based 
on clinical and immunological markers of ocular inflammation compared to controls [33-37]. 
Ohia et al. noted that 10mg/kg intramuscular sirolimus was effective in reducing endotoxin 
induced uveitis (EIU) in rabbits [37]. In Lewis rats, Roberge found that intravenous sirolimus 
could prevent induction of experimental autoimmune uveitis (EAU) at doses down to 
0.1mg/kg/d [35]. In two other studies of EAU in Lewis rats, efficacy of sirolimus was shown 
when the drug was studied as a combination therapy [33,34]. Ikeda et al. found that 
prevention of clinical EAU was achieved in 20% eyes with tacrolimus (0.1mg/kg/d), 50% eyes 
with sirolimus (0.1mg/kg/d), and 100% eyes with both drugs [33]. Martin et al. conducted a 
similar study in which they showed that EAU was prevented in 100% eyes treated with 
sirolimus (0.01mg/kg/d) and ciclosporin (2mg/kg/d), whereas most developed the disease if 
treated with either agent alone [34]. They also demonstrated marked synergism between 
sirolimus and ciclosporin for inhibition of proliferation of retinal S-antigen primed 
lymphocytes in vitro [34]. The authors argue that this potential synergistic effect between 
mTOR inhibitors and calcineurin inhibitors may have implications for its clinical use [33,34]. 
 
One cautionary note comes from an EAU study in B10.RIII mice which compared low 
(1.5ug/d) vs high (7.5ug/d) sirolimus. Although high dose sirolimus significantly suppressed 
uveitis, low dose sirolimus appeared to worsen the uveitis compared to controls [36]. The 
authors suggest that low doses of sirolimus may alter T-cell dynamics to enhance the 
effector T-cell response, rather than inhibiting it, but the exact mechanism remains unclear 
[36]. This has not been repeated in other studies, and may be a feature specific to this 
model. Assuming that these six-week old mice were around 20g, these doses equate to 
around 0.075mg/kg/d and 0.375mg/kg/d, thus the lower dose which caused worsening of 
disease in the mouse is similar to the doses which cause significant benefit in the rat model 
[33,35]. 
 
In the sole human in vitro study, Yang et al. cultured peripheral blood mononuclear cells 
collected from uveitis patients with Vogt-Koyanagi-Harada Syndrome, in various 
concentrations of sirolimus ranging from 1 to 1000 ng/ml [38]. The study used control 
groups of the cells cultured in equivalent concentrations of dexamethasone. The authors 
found that sirolimus had a significantly greater effect at suppressing inflammatory cytokines 
than dexamethasone, and could completely suppress IL-17 production at doses as low as 
10ng/ml [38].  
 
Sirolimus – clinical studies 
The clinical use of sirolimus for non-infectious uveitis is currently reported in three 
prospective open label trials (one Phase 2 randomised comparative open label trial, and two 
non-comparative Phase 2 trials) and three retrospective studies (one case series, and two 
case reports). The Phase 2 comparative open label trial (the SAVE study) comprises three 
separate reports. No blinded randomised controlled trials (RCTs) studying the use of 
sirolimus for non-infectious uveitis were identified by the searches. 
In total these studies comprise 46.87 patient-years of analysis, using data collected from a 
total of 53 patients, comprising a wide range of uveitis diagnoses (documented in Table 2).  
 
Of the three prospective studies, the primary outcome was generally based on clinical 
scores of inflammation and reflected the target group of uveitis patients (vitreous haze in 
one, anterior chamber cells in one, and a multi-component endpoint in one). Additional 
secondary outcomes included the reporting of adverse events, corticosteroid use, the need 
for additional therapy, and changes in fluorescein angiography. Locally administered 
sirolimus regimens were provided either by intravitreal injection or subconjunctival 
injection. Local doses featuring in the studies ranged from 352µg as an intravitreal injection 
to 1320µg as a subconjunctival injection. Three studies used systemic sirolimus, all orally. 
Systemic doses ranged from 1mg to 12mg daily. 
 
Due to the range of study designs, sirolimus regimens and trial endpoints, direct comparison 
of studies is problematic and meta-analysis is not possible. The data is therefore provided 
below as a narrative. 
 
Intravitreal and subcutaneous injection of sirolimus 
The use of intravitreal and subcutaneous administration of sirolimus was investigated in two 
prospective studies. The SAVE study [40,41,42] was a randomised open label trial comparing 
two monthly subcutaneous vs intravitreal sirolimus with a primary endpoint at 6 months, 
and then a further 6 months extension during which treatment could be continued at the 
investigator’s discretion. The primary efficacy outcome was a reduction of vitreous haze by 
2 points (in those with active uveitis at baseline), or the maintenance of no clinical vitreous 
haze (in those with inactive disease at baseline). The SAVE study comprised a total of 30 
patient-years of analysis. 
At six months, combining both sirolimus treatment groups together, the study reported that 
the primary efficacy outcome was met in 8/20 (40%) of those with active uveitis and 7/8 
(88%) patients who were inactive at baseline [42]. At 12 months the primary efficacy 
outcome was met in 14/20 (70%) in the active uveitis patients, and 7/8 (88%) in the inactive 
patients [41]. There were no significant differences in efficacy between the intravitreal and 
subconjunctival groups [41,42]. 
 
Quality of life was assessed as a secondary outcome of the SAVE study, evaluated by the 
visual function questionnaire NEI VFQ-39 [40]. Both the intravitreal and subconjunctival 
groups reported improvements in pain over 12 months, but only the intravitreal group had a 
significant improvement in the overall composite score, which includes other life factors. 
The authors suggest that intravitreal administration of sirolimus may be superior for ‘vision-
related health’ [40].  
 
Evaluation of visual acuity and macular thickness showed a mixed picture. In terms of 
LogMAR VA, at six months 30% gained one or more lines, 50% remained stable, and 20% 
lost one or more lines; at 12 months these figures were 52%, 24%, and 24% respectively. Of 
those with macular oedema at baseline (n=11/20 of active uveitis), 6/11 showed 
improvement in central macular thickness (CMT) at month 3, but only 2/11 showed 
improvement at month 6; indeed the mean CMT for the macular oedema group showed no 
significant improvement at either the 6 month or the 12 month time-point [41,42]. At 
baseline 20 patients were taking corticosteroids, of whom 13/20 were taking > 10mg/d; at 6 
months only 2 were still requiring >10mg/d; at 12 months only one patient was still 
requiring >10mg/d, and 5/20 (25%) were reported to have stopped their steroid use entirely 
[41]. 
 
There were 6/30 (20%) patient discontinuations from the SAVE study, of which one was due 
to drug failure, one due to death (not considered to be related to the study drug), one 
patient had progression of a pre-existing macular oedema, and three were loss of follow-up 
or patient transport issues [41]. Various adverse events (AEs) and reactions (ARs) were 
reported that are discussed below. Serious adverse events (SAEs) included perioperative 
death, shoulder debridement, vitrectomy, infective myocarditis, myocardial infarction, and 
exacerbation of sarcoidosis. There were no serious adverse reactions (SARs). 
The authors conclude that local sirolimus, both by intravitreal and subconjunctival injection, 
is safe and well-tolerated in patients with uveitis, and appears to be effective in reducing 
inflammation but that further work is needed to evaluate efficacy. 
 
Sen et al. produced a non-comparative open label trial of subconjunctival sirolimus for 
anterior uveitis, studying a small population of 5 patients with 1.67 patient-years of analysis 
[43]. All 5 patients had non-infectious uveitis and were taking steroids. Sirolimus was 
administered as a one-off 1320µg subconjunctival injection. The primary outcome was a 
reduction of anterior chamber inflammation at 4 weeks, measured by a 2-step reduction in 
anterior cells. Efficacy was shown by meeting this outcome in 3/5 (60%) patients, with the 
other 2 patients showing a 1-step reduction in the 4 week period [43]. 
Secondary outcomes included visual acuity, fluorescein angiography, and retinal thickness. 
Visual acuity improved by at least one line in 4/5 (80%). No significant changes were 
reported regarding angiography or retinal thickness on OCT [43]. No patients discontinued 
the study. There were four ARs related to the subconjunctival injection process (injection 
site irritation (3) and chemosis (1)), but no SAEs or SARs [43]. Sen et al. conclude that 
sirolimus was well-tolerated and that its potential efficacy in uveitis should be explored in 
further studies [43]. 
 
Oral administration of sirolimus 
The use of oral sirolimus is reported in one prospective study, one case series and two case-
reports. A phase 2 non-comparative open label trial by Shanmuganathan et al. evaluated a 
regimen of oral sirolimus on a population of eight patients with uveitis refractory to usual 
treatment, comprising 7.6 patient-years of analysis [44]. The regimen involved a starting 
dose of 4mg sirolimus per day, which could be altered in 2mg increments as dictated by 
blood sirolimus levels and clinical activity. Doses provided ranged from 2mg to 12mg per day 
[44]. 
The primary outcome was improvement in one or more of symptoms, visual acuity, specific 
signs of inflammation and reduction of corticosteroids. Efficacy was reported in 5/8 (63%) 
patients all of whom were able to reduce their steroid doses to below 10mg per day; in two 
of these patients sirolimus appeared to induce a state of uveitis remission with successful 
tapering of all treatment (including sirolimus). The treatment was deemed to have failed in 
the remaining 3 patients due to symptomatic progression of the uveitis and an AR, and one 
patient discontinued the study due to an AR [44]. There were no SAEs or SARs. The rate of 
ARs was relatively high in this study and generally occurred when trough levels were 
significantly above that recommended; there is no established recommendation for uveitis 
but for renal transplantation the recommended level is <20ng/ml [44]. The authors conclude 
that oral sirolimus appears to be effective in treatment-resistant uveitis but that further 
study is needed [44]. 
 
Phillips et al. report a case-series of 8 patients with uveitis who were treated with oral 
sirolimus using doses of 1 to 4mg per day to achieve blood trough levels of 4-12ng/ml 
(significantly lower than the levels used in transplantation) [45]. Treatment was for an 
average of 44.5 weeks. The authors reviewed records for levels and flare-ups of eye 
inflammation and steroid use as primary outcomes, alongside symptoms, visual acuity, and 
available imaging [45]. Efficacy was reported in 4/8 (50%) patients as improving all primary 
outcomes; however 3 of these required a sirolimus and methotrexate co-therapy to achieve 
this [45]. Of the other 4 patients, 1 discontinued as a loss to follow up, and 3/8 (38%) were 
deemed to have failed on sirolimus treatment as they discontinued due to ARs [45]. All 3 
ARs (a DVT, excessive nausea and vomiting, and a case of thrombocytopenia) were deemed 
to be side effects of the sirolimus treatment; however none were SARs [45]. Phillips et al. 
conclude that although it appeared to be effective in some cases of uveitis, its use might be 
limited by the high rate of adverse events even at low doses [45]. 
 
Two case reports outlining the use of sirolimus in uveitis were identified [46,47]. 
Nussenblatt reported the use of oral sirolimus in a patient with Punctate Inner Choroiditis 
(PIC) that had previously been treated with intraocular steroids [46]. Sirolimus was used at 
an initial loading dose of 6mg, followed by a regime of 2mg every 2 days for 3 weeks, and 
then 4mg every 2 days for 4 months [46]. The authors report that a notable reduction in 
retinal thickness was detected, and improvement of appearance on fluorescein angiography 
also occurred, indicating improvement of the inflammatory state [46]. These changes 
continued for at least 5 months after the treatment stopped, and throughout the follow up 
period the patient’s visual acuity remained stable [46]. 
 
The second case report documents a case of acute idiopathic uveitis which was refractory to 
corticosteroids [47]. This case was then subsequently treated with a combination therapy of 
sirolimus and cyclophosphamide, which is reported to have led to remission and retention 
of visual acuity [47]; however the full text of this case report was unobtainable and is not 
included in further analysis. 
 
Everolimus – preclinical study 
One relevant preclinical study of the use of everolimus in uveitis was identified. In the EAU 
mouse model Hennig et al. evaluated oral everolimus given at a dose of 5mg/kg, starting 
either two days before or 14 days after induction of EAU [39]. Treatment with everolimus 
significantly reduced the frequency and severity of development of EAU when compared to 
controls, which was associated with an increase in regulatory T-cells and reduction in the 
levels of inflammatory cytokines [39].  
 
Everolimus – clinical study 
There are no RCTs reported for the use of everolimus for non-infectious uveitis in humans. 
There is one phase 2 non-comparative open label clinical trial which included 12 patients 
with idiopathic uveitis (18 patient-years of analysis). The trial used a twice daily everolimus 
regimen titrated upwards from 1.5mg to 2.5mg max daily dose to achieve a serum trough 
level of 3-8ng/ml, with doses guided by blood measurements [48]. The primary outcome 
was a clinical evaluation for the inactivity of uveitis (based on any of AC cells, vitreous 
snowballs and chorioretinal lesions). Additional secondary outcomes assessed were the 
complications, the clinical course of disease, the use of alternative treatments (including 
steroids) and reporting of adverse events. The primary efficacy endpoints was met in 12/12 
(100%) patients at 3 months, and 6/11 (55%) at 12 months [48]. 
 
 At baseline all patients were taking ciclosporin and high doses of steroids. The study found 
that everolimus allowed reduction of both of these drugs [48]. All patients reduced steroid 
doses by 12 months, with complete withdrawal in 4/12 (33%) and doses less than 10mg/day 
in 8/12 (67%). Ciclosporin could be withdrawn in 3/12 (25%) and was reduced to less than 
half dose in 8/12 (67%) [48]. The study also assessed visual acuity, vitreous cells, vitreous 
haze, and fluorescein angiography as secondary outcomes. However none of these 
displayed statistically significant changes [48]. 
 
One patient (8.33%) discontinued prior to the end of the trial, attributed to a patient 
decision not related to the everolimus therapy. A number of AEs and ARs were also reported 
which are included below. There were no SAEs or SARs. 
The authors conclude that everolimus appears effective for refractory uveitis, and 
recommend that a full RCT be done to further evaluate its use for uveitis [48]. 
 
Study Discontinuations and Adverse Events 
An important marker of the safety of these drugs in humans is, the rate of discontinuation 
(and the reasons for this including adverse drug reactions), and the overall rate and severity 
of adverse events. 
 
Overall from the clinical studies, 12 study discontinuations occurred: 11 from sirolimus 
studies, and 1 from the everolimus study. The sirolimus clinical studies totalled 53 patients 
and 46.87 patient-years of analysis; therefore the discontinuation rate of sirolimus patients 
is 20.8% of patients, or 0.235 discontinuations per patient-year. The discontinuation rate for 
oral sirolimus was 27.8% of patients, or 0.329 discontinuations per patient-year; for local 
(subconjunctival or intravitreal) sirolimus the rate was 17.1% of patients, or 0.189 
discontinuations per patient-year. The everolimus clinical study was made up of 12 patients 
and 18 patient-years of analysis; therefore the discontinuation rate of everolimus is 8.3% of 
patients, or 0.056 discontinuations per patient-year. 
It should be noted that many of the discontinuations are not due to treatment failure or an 
adverse reaction to the drug, but related to patient choice or practical aspects that affected 
their ability to continue (illustrated in Table 3). Only 4/12 discontinuations were deemed to 
be caused by the study drug, comprising a case of Deep Vein Thrombosis (DVT), a case of 
excessive nausea and vomiting, a case of thrombocytopenia, and a case of scleroderma-like 
skin changes. Taking these discontinuations in isolation, the sirolimus discontinuation rate 
becomes 7.5% of patients and 0.085 per patient-year; there were no drug-related 
discontinuations for everolimus. 
 
Table 3. Clinical study discontinuations by reported cause 
Cause of discontinuation Discontinuations 
on sirolimus 
Discontinuations 
on everolimus 
Total 
Ophthalmic reasons    
Lack of clinical improvement 1 0 1 
Exacerbation of macular oedema 1 0 1 
Medical reasons   
Deep Vein Thrombosis 1 0 1 
Nausea +/- vomiting 1 0 1 
Scleroderma 1 0 1 
Thrombocytopenia 1 0 1 
Unrelated death 1 0 1 
Other reasons    
Loss to follow up 3 0 3 
Patient decision 0 1 1 
Patient transport problem 1 0 1 
Total 11 1 12 
 
In addition to discontinuations, various adverse events and reactions (AEs and ARs) were 
reported. Most reports (and all of the serious reports) were deemed to be unrelated to the 
study drug. In total there were 65 reported AEs; 53 occurring with sirolimus therapy and 12 
with everolimus, representing an adverse event rate of 1.131 per patient-year with 
sirolimus, and 0.666 per patient-year with everolimus. 
However, of the 65 AEs, only 32 were thought to have a high likelihood of having been 
caused by the studied drug or delivery method and considered as ARs (Table 4). 30 ARs 
occurred in the sirolimus studies, and 2 in the everolimus study. This represents an adverse 
reaction rate of 0.640 per patient-year for sirolimus (0.505 per patient-year for local 
sirolimus, 0.921 per patient-year for oral sirolimus) and 0.111 per patient-year for 
everolimus.  
 
Most ARs were encountered using oral routes of administration, and tended to be systemic 
rather than ocular. In comparison, ARs of the locally administered drugs were dominated by 
expected consequences of the injection method, rather than the studied drug [41]. 
Gastrointestinal effects accounted for 4/16 (25%), and dermatological effects 5/16 (31%), of 
ARs reported in patients receiving mTOR inhibitors orally. Gastrointestinal effects, 
dermatological effects, DVT and thrombocytopenia are known side effects of mTOR 
inhibitors when taken orally [44,45]. 
Other ARs encountered that are more unusual include 2 cases of headaches, and 1 case 
each of deranged LFTs, myalgia, recurrent infection, and scleroderma. These comprise 6/16 
(38%) of the ARs reported in patients taking mTOR inhibitors orally. 
 
Table 4. Adverse drug reactions and procedure-related adverse events reported in the 
included clinical studies 
Adverse Reaction IVT 
sirolimus 
SCJ 
sirolimus 
Oral 
sirolimus 
Oral 
everolimus 
Total 
Abdominal pain 0 0 1 1 2 
Acne 0 0 1 0 1 
Chemosis 0 1 0 0 1 
DVT 0 0 1 0 1 
Eczema 0 0 1 0 1 
Erythema nodosum 0 0 1 0 1 
Floaters 4 0 0 0 4 
Headache 0 0 1 1 2 
LFT derangement 0 0 1 0 1 
Myalgia 0 0 1 0 1 
Nausea +/- vomiting 0 0 2 0 2 
Ocular pain 1 0 0 0 1 
Recurrent respiratory infection 0 0 1 0 1 
Scleroderma-like changes 0 0 1 0 1 
SCJ injection site irritation 0 9 0 0 9 
Seborrheic dermatitis 0 0 1 0 1 
Subconjunctival haemorrhage 1 0 0 0 1 
Thrombocytopenia 0 0 1 0 1 
Total 6 10 14 2 32 
Note: some adverse reactions may have occurred in the same patient. 
IVT is Intravitreal; SCJ is Subconjunctival; DVT is Deep Vein Thrombosis; LFT is Liver Function 
Test. 
  
Discussion 
This comprehensive review summarises the available evidence for the use of mTOR 
inhibitors in the management of non-infectious uveitis. At present, potential use of sirolimus 
and everolimus in uveitis treatment pathways is limited by the paucity of RCTs in this field. 
 
The studies evaluated here provide some evidence that sirolimus and everolimus may be 
effective in suppressing active uveitis, and reducing the dose of corticosteroid or other 
immunomodulatory therapy required to achieve disease control. Reported efficacy across 
these endpoints ranges from 40% to 100%. Only one preclinical study documented a 
worsening of uveitis with sirolimus, however this only occurred only at very low doses, and 
as discussed above may be a feature of the animal model [36]. 
 
Sirolimus and everolimus appear to be well tolerated; the incidence of side effects was 
significantly higher in patients taking an mTOR inhibitor orally rather than by intravitreal or 
subconjunctival injection (0.921 per patient-year and 0.505 per patient-year, respectively) 
attributed to the wider systemic absorption of the drugs by this method of administration. 
Local administration is thus likely to become the preferred method of use in the future 
management of uveitis. On the whole, mTOR inhibition appears to be well tolerated, with 
no drug-related serious adverse reactions occurring in the included studies. 
It is interesting to compare the adverse event rate to the major alternatives for 
corticosteroid-sparing therapy in uveitis. The recent VISUAL I randomised controlled trial for 
the use of adalimumab in uveitis reported an AE rate of 1052.4 per 100 patient-years (10.52 
per patient-year) [49]. This is significantly higher than our current review’s suggested AE 
rate for mTOR inhibitors, which is 1.131 per patient-year for sirolimus and 0.666 per patient-
year for everolimus. However it should be recognised that this is not a direct comparison 
within the same study, and that there are differences in the populations sampled and the 
methodologies used. 
A recent trial of methotrexate and mycophenolate mofetil in non-infectious uveitis reported 
AEs in 33/41 patients receiving methotrexate, and 32/39 patients receiving mycophenolate 
mofetil, with a follow up of 6 months [50]. The trial comprises an analysis of 20.5 patient-
years for methotrexate and 19.5 patient-years for mycophenolate mofetil, as a result 
representing a methotrexate AE rate of 1.608 per patient-year and mycophenolate mofetil 
AE rate of 1.641 per patient-year. Both of these rates are higher, although in the same order 
of magnitude, than those found for the mTOR inhibitors in this review, although again the 
same cautions apply. Overall however, these studies do suggest that mTOR inhibitors seem 
to have acceptable rates of adverse events in the studied populations. 
 
Corticosteroids currently form the mainstay of treatment in uveitis, used both as ‘rescue 
therapy’ for acute disease flares, and as long-term therapy in chronic disease. 
Corticosteroids have many desirable features, including speed of onset and efficacy in both 
local and systemic forms: in the MUST trial disease inactivity was reported in 88% eyes 
randomised to the fluocinolone acetonide implant and in 71% eyes randomised to systemic 
corticosteroid usage [51]. They do however have an unfavourable side-effect profile, with 
adverse systemic effects being more common and of greater severity with increasing dose 
and duration of use. There has been a longstanding desire to develop alternative 
immunomodulatory therapies with improved side-effect profiles whilst achieving similar 
efficacy to corticosteroids; these agents are often referred to as “steroid-sparing agents”, as 
they often enable reduction in concurrent steroid dosage. Unfortunately, currently available 
steroid-sparing agents are often associated with different, but equally severe side effects, 
and in many cases lack both the speed of onset and efficacy of corticosteroids.  
 
In general, locally administered agents achieve rapid onset and as demonstrated in this 
review, tend to be associated with fewer systemic side-effects; locally administered mTOR 
inhibitors therefore offer an attractive option as potential steroid-sparing 
immunomodulatory therapy in uveitis. 
 
The potential for mTOR inhibitors in this role is being recognised, as reflected by the level of 
ongoing study into the area. The SAKURA study (NCT01358266) is a phase 3 multicentre, 
randomised and double-blinded study of sirolimus for active non-infectious uveitis [52,53]. 
The SAKURA study is expected to report initial efficacy data in late 2016, with an associated 
safety study due to report in 2017 [52,54]. This will be the largest study of mTOR inhibition 
in uveitis to date (in terms of patient population and patient-years of analysis) and is likely 
to provide robust evidence to guide further use of sirolimus in uveitis treatment protocols. 
  
Screening of international trial registries also identified two other studies which were 
registered but for which the results have not been published. The SAVE-2 trial 
(NCT01280669) is registered as a randomised phase 2 trial comparing 440µg to 880µg 
intravitreal sirolimus [55]; this was registered in 2011 and there are currently no updates on 
ClinicalTrials.gov so it is not clear if this is ongoing. Another trial was registered on EudraCT 
in 2006 outlining an investigation into oral everolimus, but this is recorded as having been 
cancelled [56]. The potential relevance of mTOR inhibitors to health policy in regard to 
uveitis is shown by the fact that in 2015 the National Institute for Health and Care 
Excellence (NICE), a public body that guides clinical practice in the UK, commissioned a 
‘Multiple Technology Appraisal’ to evaluate a number of agents for the management of non-
infectious uveitis which would include intravitreal sirolimus; however in 2016 intravitreal 
sirolimus was withdrawn from this particular MTA, which is now focussed on the use of 
subcutaneous adalimumab and an intravitreal dexamethasone implant (Ozurdex) [57]. The 
outcome of this appraisal is scheduled to be published in July 2017. 
 
As mentioned above, one preclinical study identified a worsening of uveitis with low dose 
sirolimus. It is therefore interesting to note that a potentially pro-inflammatory effect of 
sirolimus has also been described by Valle et al. in a type 1 diabetes mellitus NOD (non-
obese diabetic) mouse model [58]. The study aimed to investigate sirolimus as an 
immunomodulatory adjunct for diabetic mice treated with anti-CD3 antibodies. However 
they encountered significant worsening of glycaemic control and disruption of T cell 
tolerance [58]. The authors suggest that this may be due to the inhibition of IL-2 
transduction by sirolimus, which they state is necessary for the effects of the anti-CD3 
therapy in the mouse model [58]. 
However, the results of this study have been contradicted by a more recent study by Perl et 
al. [59]. Perl et al. found that sirolimus and anti-CD3 co-therapy resulted in improved long-
term control of diabetic NOD mice, although documented a similar initial worsening of 
glycaemic state. The authors discussed the Valle et al. study, and suggested that the 
previous results may be caused by a directly toxic action on pancreatic beta cells posed by 
sirolimus, rather than an immune mediated effect [59]. However Perl et al. concluded that 
the ability of sirolimus to provide immune tolerance to beta cells in the setting of diabetes is 
unclear [59]. Further research may therefore be required to establish if a pro-inflammatory 
sirolimus effect occurs outside of a mouse model. 
 
It is also intriguing to note that the synergistic effect of mTOR inhibition provided alongside 
calcineurin inhibitors described in pre-clinical study by Ideka et al. [33] and Martin et al. [34] 
is not solely limited to experimental uveitis. Ideka et al. added tacrolimus, while Martin et al. 
added ciclosporin, and both of these calcineurin inhibitors have been documented 
elsewhere to provide benefit for autoimmune disease in combination with mTOR inhibition 
[60,61]. Warner et al. have shown synergistic action between sirolimus and ciclosporin for 
the treatment of systemic lupus erythematosus in a mouse model [60], while Shapiro et al. 
have shown synergism between sirolimus and tacrolimus for NOD mouse models of type 1 
diabetes mellitus [61]. This indicates a potential for co-therapy that could extend to human 
autoimmune disease, which may have an effect on reducing adverse events. 
 
While considering preclinical studies of experimental uveitis treatments, it is worthwhile 
mentioning other mechanisms of current interest in this field, in addition to 
immunomodulation via mTOR inhibition. Of particular recent interest is the 
immunomodulatory molecule VGX-1027, which seems to exhibit properties that antagonise 
the activation of the Toll-Like Receptor 4 (TLR4) [62]. It is thought that this occurs by 
reducing antigen presentation [62], while studies have also shown effects on intracellular 
signalling pathways [63]. Preclinical trials of VGX-1027 have shown efficacy for models of 
autoimmune disease, particularly inflammatory bowel disease, type 1 diabetes mellitus and 
rheumatoid arthritis [62]. From an ophthalmological viewpoint, Mangano et al. have studied 
VGX-1027 use in a Lewis rat model of uveitis, and found evidence for a reduction of ocular 
inflammation [64]. 
Another mechanism of interest regards the role of carbon monoxide in inflammatory 
disease; exogenous CO may assist in the control of autoimmune conditions [65]. Fagone et 
al. have studied the use of the CO-releasing molecule CORM-A1 in a rat model of uveitis, 
and found a significant improvement of ocular inflammation [65]. 
Both of these mechanisms are in the early stages of being potential contenders for non-
infectious uveitis treatment modalities. 
 
This review is particularly limited by the low evidence level of the literature currently 
available. Most studies included were non-comparative trials, and of the few comparative 
studies included, none were masked increasing the risk of performance and detection 
biases. Additionally, the field of study of mTOR inhibition for uveitis is relatively small, 
reflected in the low number of studies that could be included, and the low combined 
patient-years of analysis that this review represents (64.87 patient-years of combined 
clinical analysis). This is due to a combination of short follow-up periods and small study 
populations, both of which are restrictions in the available literature in this field currently. 
As a result, our ability to derive robust conclusions regarding wider use of mTOR inhibitors 
in uveitis is limited. 
The wide range of mTOR inhibitor doses featured in this review is also a potential limitation. 
Doses were particularly varied for studies of oral sirolimus, which ranged from 1mg 
sirolimus per day in a case series by Phillips et al. [45], to 12mg sirolimus per day in a trial by 
Shanmuganathan et al. [44]. Further research into a sirolimus dose-response relationship in 
the setting of non-infectious uveitis may be needed to investigate for the relevance of this 
variable. 
Full texts for two studies identified by the searches were unable to be obtained for this 
review, despite attempts to contact the authors and publishing bodies directly. Since these 
comprised only one preclinical study [37] and a single case report [47], these would not 
have significantly contributed to the evidence, and there is no indication in the abstracts 
that they would have contradicted the conclusions of other included studies. 
 
The varied aetiologies of patients with non-infectious uveitis is an underlying difficulty when 
undertaking research in this field. Uveitis is a heterogeneous group of disorders rather than 
a single aetiological entity, an aspect which is seen within the studies presented in this 
review (illustrated in Table 2). 
As interest in this field grows, a more consistent range of uveitis diagnoses may emerge, and 
consideration of efficacy of interventions, such as the mTOR inhibitors, in clearly defined 
subgroups may inform the development of subgroup-targeted therapies and improved 
outcomes for patients. 
 
Conclusion 
In conclusion, this comprehensive review provides some support for the use of mTOR-
inhibitors in the management of non-infectious uveitis, being well tolerated, particularly 
when delivered locally. Whilst the review found limited evidence for the efficacy of sirolimus 
and everolimus, there is a clear need for further study in this area, particularly in the form of 
well-designed RCTs. To this end, we await the results of the SAKURA study which will 
provide much-needed evidence of the potential role for mTOR inhibitors in contemporary 
treatment protocols for the management of non-infectious uveitis. 
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